Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology)

Autor: Süner A., Aydin D., Hacioglu M.B., Dogu G.G., Imamoglu G.I., Menekşe S., Pilanci K.N.
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Male
cancer patient
prostate adenocarcinoma
vomiting
castration resistant prostate cancer
drug safety
peripheral neuropathy
Turkey
retrospective study
very elderly
diarrhea
thrombocytopenia
orchiectomy
granulocyte colony stimulating factor
taxoid
cancer control
cancer diagnosis
middle aged
docetaxel
Neoplasm Metastasis
cancer survival
medical society
disease free survival
antineoplastic agent
Aged
80 and over
progression free survival
Cabazitaxel
Prostate cancer
adult
prednisolone
clinical trial
nausea
anemia
aged
Prostatic Neoplasms
Castration-Resistant
Treatment Outcome
anorexia
disease severity
epidemiology
Taxoids
overall survival
Antineoplastic Agents
Article
cancer chemotherapy
cancer growth
Disease-Free Survival
Chemotherapy
neutropenia
metastasis
Humans
controlled study
drug fatality
human
drug dose reduction
survival time
metastasis potential
Retrospective Studies
treatment response
cancer center
major clinical study
mortality
human tissue
drug efficacy
febrile neutropenia
multicenter study
Toxicities
Turk (people)
antiandrogen
fatigue
pathology
Popis: OBJECTIVE: Prostate cancer is among the most common cancers in males. Prostate cancer is androgen dependent in the beginning, but as time progresses, it becomes refractory to androgen deprivation treatment. At this stage, docetaxel has been used as standard treatment for years. Cabazitaxel has become the first chemotherapeutic agent which has been shown to increase survival for patients with metastatic Castrate Resistant Prostate Cancer (mCRPC) that progresses after docetaxel. Phase 3 TROPIC study demonstrated that cabazitaxel prolongs survival. PATIENTS AND METHODS: In this study, we evaluated a total of 103 patients who took cabaz-itaxel chemotherapy for mCRPC diagnosis in 21 centers of Turkey, retrospectively. This study included patients who progressed despite doc-etaxel treatments, had ECOG performance score between 0-2, and used cabazitaxel treatment. Patients received cabazitaxel 25 mg/m2 at every 3 weeks, and prednisolone 5 mg twice a day. RESULTS: Median number of cabazitaxel cures was 5.03 (range: 1-17). Cabazitaxel response evaluation detected that 34% of the patients had a partial response, 22.3% had stable disease and 32% had a progressive disease. Grade 3-4 hema-tological toxicities were neutropenia (28.2%), neutropenic fever (14.5%), anemia (6.7%), and thrombocytopenia (3.8%). In our study, median progression-free survival (PFS) was 7.7 months and overall survival (OS) was 10.6 months. CONCLUSIONS: This study reflects toxicity profile of Turkish patients as a Caucasian race. We suggest that cabazitaxel is a safe and effective treatment option for mCRPC patients who progress after docetaxel. Moreover, ethnicity may play important roles both in treatment response and in toxicity profile.
Databáze: OpenAIRE
Externí odkaz: